Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
41 hedge funds and large institutions have $350M invested in Centessa Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 9 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
2.94% less ownership
Funds ownership: 79.33% → 76.38% (-2.9%)
7% less funds holding
Funds holding: 44 → 41 (-3)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
48% less capital invested
Capital invested by funds: $669M → $350M (-$319M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$32.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$2.76M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.38M |
| 5 |
JP Morgan Chase
New York
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$32.1M |
| 2 |
Janus Henderson Group
London,
|
-$14M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.45M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.52M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.95M |
CNTA Hedge Fund Activity: Q2 2022 in Review
41 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2022, worth a combined $350M — down 48% from $669M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CNTA and 7 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 14 added.
The largest buyer was BVF Inc, adding an estimated $32.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $32.1M sold.
- 41 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2022, down from 44 in Q1 2022.
- Funds reported $350M of Centessa Pharmaceuticals stock for Q2 2022, down 48% quarter-over-quarter.
- 7 funds opened new Centessa Pharmaceuticals positions in Q2 2022 and 9 closed out, a net change of -2 holders.
- The largest Centessa Pharmaceuticals buyer in Q2 2022 was BVF Inc, an estimated $32.9M added.
- The largest Centessa Pharmaceuticals seller in Q2 2022 was RA Capital Management, an estimated $32.1M sold.
Based on aggregated 13F filings for Q2 2022.